Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide
Objectives Currently, multiple myeloma (MM) is an incurable disease. Despite the fact that arsenic trioxide (ATO) shows promising results in vitro, data from treatment of patients with MM are disappointing. Due to these discrepancies, we compared the efficacy and selectivity of ATO at two different...
Gespeichert in:
| Veröffentlicht in: | Hematology (Luxembourg) 2014-09, Vol.19 (6), p.346-351 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 351 |
|---|---|
| container_issue | 6 |
| container_start_page | 346 |
| container_title | Hematology (Luxembourg) |
| container_volume | 19 |
| creator | Reberšek, Katarina Žontar, Darja Marija Černelč, Peter Podgornik, Helena |
| description | Objectives
Currently, multiple myeloma (MM) is an incurable disease. Despite the fact that arsenic trioxide (ATO) shows promising results in vitro, data from treatment of patients with MM are disappointing. Due to these discrepancies, we compared the efficacy and selectivity of ATO at two different concentrations in samples from MM patients.
Methods
The extent of apoptosis induced by 2 and 5 µM ATO was evaluated by flow cytometry using annexin V. 34 diagnostic bone marrow samples obtained from MM patients were analysed.
Results
5 µM ATO efficiently induced apoptosis in primary samples. Besides efficacy, also selectivity of action on MM cells in comparison to remaining haematopoietic cells was demonstrated for 5 µM ATO but not for 2 µM ATO.
Discussion
Our study on primary samples confirmed that ATO has a potential role in therapeutic management of MM. Further controlled studies on MM patients are needed. |
| doi_str_mv | 10.1179/1607845413Y.0000000134 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_24165827</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1549179054</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-c6cec392c3a09bc3a558c76358c7cab1e74e4f9350eaffb6bcde84fcbf4a50493</originalsourceid><addsrcrecordid>eNqFkE1LxDAQhoMo7rr6F5YcvXRN2qTdHpfFL1jwoB4EIaTpBCJpU5NW7b-3pavuzRwmYd53ZjIPQktKVpRm-RVNSbZmnNHkZUWmQxN2hOajEI3K8cF7hs5CeCMkjklGTtEsZjTl6zibo9dHsKBa8wFYNq5pXTABO42rzramsYCrHqyrJFZgbcCmxo03lfQ9DrIa9DFVdgpKXPRY-gC1Ubj1xn2ZEs7RiZY2wMX-XqDnm-un7V20e7i93252kWI0ayOVKlBJHqtEkrwYIudrlaXJGJUsKGQMmM4TTkBqXaSFKmHNtCo0k5ywPFmgy6lv4917B6EVlQnjh2UNrguCcpYP0AhngzWdrMq7EDxosd9HUCJGsuKArPgjOxQu9zO6ooLyt-wH5WDYTAZTa-cr-em8LUUre-u89rJWJojknyHfEbuKbA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1549179054</pqid></control><display><type>article</type><title>Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Reberšek, Katarina ; Žontar, Darja Marija ; Černelč, Peter ; Podgornik, Helena</creator><creatorcontrib>Reberšek, Katarina ; Žontar, Darja Marija ; Černelč, Peter ; Podgornik, Helena</creatorcontrib><description>Objectives
Currently, multiple myeloma (MM) is an incurable disease. Despite the fact that arsenic trioxide (ATO) shows promising results in vitro, data from treatment of patients with MM are disappointing. Due to these discrepancies, we compared the efficacy and selectivity of ATO at two different concentrations in samples from MM patients.
Methods
The extent of apoptosis induced by 2 and 5 µM ATO was evaluated by flow cytometry using annexin V. 34 diagnostic bone marrow samples obtained from MM patients were analysed.
Results
5 µM ATO efficiently induced apoptosis in primary samples. Besides efficacy, also selectivity of action on MM cells in comparison to remaining haematopoietic cells was demonstrated for 5 µM ATO but not for 2 µM ATO.
Discussion
Our study on primary samples confirmed that ATO has a potential role in therapeutic management of MM. Further controlled studies on MM patients are needed.</description><identifier>ISSN: 1607-8454</identifier><identifier>EISSN: 1607-8454</identifier><identifier>DOI: 10.1179/1607845413Y.0000000134</identifier><identifier>PMID: 24165827</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Annexin V ; Antineoplastic Agents - pharmacology ; Apoptosis ; Apoptosis - drug effects ; Arsenic trioxide ; Arsenicals - pharmacology ; Bone Marrow - drug effects ; Bone Marrow - pathology ; Cells, Cultured ; Female ; Humans ; Male ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Multiple Myeloma - pathology ; Oxides - pharmacology</subject><ispartof>Hematology (Luxembourg), 2014-09, Vol.19 (6), p.346-351</ispartof><rights>W. S. Maney & Son Ltd 2014 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-c6cec392c3a09bc3a558c76358c7cab1e74e4f9350eaffb6bcde84fcbf4a50493</citedby><cites>FETCH-LOGICAL-c417t-c6cec392c3a09bc3a558c76358c7cab1e74e4f9350eaffb6bcde84fcbf4a50493</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24165827$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reberšek, Katarina</creatorcontrib><creatorcontrib>Žontar, Darja Marija</creatorcontrib><creatorcontrib>Černelč, Peter</creatorcontrib><creatorcontrib>Podgornik, Helena</creatorcontrib><title>Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide</title><title>Hematology (Luxembourg)</title><addtitle>Hematology</addtitle><description>Objectives
Currently, multiple myeloma (MM) is an incurable disease. Despite the fact that arsenic trioxide (ATO) shows promising results in vitro, data from treatment of patients with MM are disappointing. Due to these discrepancies, we compared the efficacy and selectivity of ATO at two different concentrations in samples from MM patients.
Methods
The extent of apoptosis induced by 2 and 5 µM ATO was evaluated by flow cytometry using annexin V. 34 diagnostic bone marrow samples obtained from MM patients were analysed.
Results
5 µM ATO efficiently induced apoptosis in primary samples. Besides efficacy, also selectivity of action on MM cells in comparison to remaining haematopoietic cells was demonstrated for 5 µM ATO but not for 2 µM ATO.
Discussion
Our study on primary samples confirmed that ATO has a potential role in therapeutic management of MM. Further controlled studies on MM patients are needed.</description><subject>Annexin V</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>Apoptosis - drug effects</subject><subject>Arsenic trioxide</subject><subject>Arsenicals - pharmacology</subject><subject>Bone Marrow - drug effects</subject><subject>Bone Marrow - pathology</subject><subject>Cells, Cultured</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Multiple Myeloma - pathology</subject><subject>Oxides - pharmacology</subject><issn>1607-8454</issn><issn>1607-8454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LxDAQhoMo7rr6F5YcvXRN2qTdHpfFL1jwoB4EIaTpBCJpU5NW7b-3pavuzRwmYd53ZjIPQktKVpRm-RVNSbZmnNHkZUWmQxN2hOajEI3K8cF7hs5CeCMkjklGTtEsZjTl6zibo9dHsKBa8wFYNq5pXTABO42rzramsYCrHqyrJFZgbcCmxo03lfQ9DrIa9DFVdgpKXPRY-gC1Ubj1xn2ZEs7RiZY2wMX-XqDnm-un7V20e7i93252kWI0ayOVKlBJHqtEkrwYIudrlaXJGJUsKGQMmM4TTkBqXaSFKmHNtCo0k5ywPFmgy6lv4917B6EVlQnjh2UNrguCcpYP0AhngzWdrMq7EDxosd9HUCJGsuKArPgjOxQu9zO6ooLyt-wH5WDYTAZTa-cr-em8LUUre-u89rJWJojknyHfEbuKbA</recordid><startdate>20140901</startdate><enddate>20140901</enddate><creator>Reberšek, Katarina</creator><creator>Žontar, Darja Marija</creator><creator>Černelč, Peter</creator><creator>Podgornik, Helena</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140901</creationdate><title>Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide</title><author>Reberšek, Katarina ; Žontar, Darja Marija ; Černelč, Peter ; Podgornik, Helena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-c6cec392c3a09bc3a558c76358c7cab1e74e4f9350eaffb6bcde84fcbf4a50493</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Annexin V</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>Apoptosis - drug effects</topic><topic>Arsenic trioxide</topic><topic>Arsenicals - pharmacology</topic><topic>Bone Marrow - drug effects</topic><topic>Bone Marrow - pathology</topic><topic>Cells, Cultured</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Multiple Myeloma - pathology</topic><topic>Oxides - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reberšek, Katarina</creatorcontrib><creatorcontrib>Žontar, Darja Marija</creatorcontrib><creatorcontrib>Černelč, Peter</creatorcontrib><creatorcontrib>Podgornik, Helena</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Hematology (Luxembourg)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reberšek, Katarina</au><au>Žontar, Darja Marija</au><au>Černelč, Peter</au><au>Podgornik, Helena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide</atitle><jtitle>Hematology (Luxembourg)</jtitle><addtitle>Hematology</addtitle><date>2014-09-01</date><risdate>2014</risdate><volume>19</volume><issue>6</issue><spage>346</spage><epage>351</epage><pages>346-351</pages><issn>1607-8454</issn><eissn>1607-8454</eissn><abstract>Objectives
Currently, multiple myeloma (MM) is an incurable disease. Despite the fact that arsenic trioxide (ATO) shows promising results in vitro, data from treatment of patients with MM are disappointing. Due to these discrepancies, we compared the efficacy and selectivity of ATO at two different concentrations in samples from MM patients.
Methods
The extent of apoptosis induced by 2 and 5 µM ATO was evaluated by flow cytometry using annexin V. 34 diagnostic bone marrow samples obtained from MM patients were analysed.
Results
5 µM ATO efficiently induced apoptosis in primary samples. Besides efficacy, also selectivity of action on MM cells in comparison to remaining haematopoietic cells was demonstrated for 5 µM ATO but not for 2 µM ATO.
Discussion
Our study on primary samples confirmed that ATO has a potential role in therapeutic management of MM. Further controlled studies on MM patients are needed.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>24165827</pmid><doi>10.1179/1607845413Y.0000000134</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1607-8454 |
| ispartof | Hematology (Luxembourg), 2014-09, Vol.19 (6), p.346-351 |
| issn | 1607-8454 1607-8454 |
| language | eng |
| recordid | cdi_pubmed_primary_24165827 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Annexin V Antineoplastic Agents - pharmacology Apoptosis Apoptosis - drug effects Arsenic trioxide Arsenicals - pharmacology Bone Marrow - drug effects Bone Marrow - pathology Cells, Cultured Female Humans Male Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - pathology Oxides - pharmacology |
| title | Selective apoptosis of multiple myeloma cells in primary samples induced by arsenic trioxide |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T06%3A46%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20apoptosis%20of%20multiple%20myeloma%20cells%20in%20primary%20samples%20induced%20by%20arsenic%20trioxide&rft.jtitle=Hematology%20(Luxembourg)&rft.au=Reber%C5%A1ek,%20Katarina&rft.date=2014-09-01&rft.volume=19&rft.issue=6&rft.spage=346&rft.epage=351&rft.pages=346-351&rft.issn=1607-8454&rft.eissn=1607-8454&rft_id=info:doi/10.1179/1607845413Y.0000000134&rft_dat=%3Cproquest_pubme%3E1549179054%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1549179054&rft_id=info:pmid/24165827&rfr_iscdi=true |